Clinical Trial Update: Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of Ropeginterferon alfa-2b and ruxolitinib for myelofibrosis is currently recruiting, including patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Ropeginterferon alfa-2b (ropeginterferon alfa-2b)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: The University of Hong Kong | Conditions: Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF) | Phase 2 | Status: RECRUITING